CR Bard acquires MedChem Products in stock-swap deal
This article was originally published in Clinica
CR Bard will take over MedChem Products in a stock-for-stock deal worth $100 million. Under an agreement signed on May 24th, Bard will pay $9.25 for each of the 11 million outstanding MedChem shares. This represents a 42% premium on the pre-bid price of MedChem stock which closed at $6.50 on May 23rd.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.